Azienda Ospedaliera Universitaria Federico II
Napoli, Italy
16 recruiting
Showing 1–16 of 16 trials
Recruiting
Phase 3
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Urinary Bladder NeoplasmsNeoplasm MetastasisCarcinoma, Transitional Cell
Eli Lilly and Company450 enrolled279 locationsNCT07218380
Recruiting
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
Relapsed Refractory Multiple Myeloma (RRMM)
Janssen-Cilag Ltd.900 enrolled68 locationsNCT06285318
Recruiting
Phase 2Phase 3
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Breast Neoplasms
Bristol-Myers Squibb500 enrolled293 locationsNCT06926868
Recruiting
Phase 2Phase 3
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
Urothelial Cancer
Bristol-Myers Squibb470 enrolled157 locationsNCT07106762
Recruiting
Phase 3
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Hoffmann-La Roche1,050 enrolled351 locationsNCT06065748
Recruiting
Phase 3
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Breast NeoplasmsNeoplasm Metastasis
Eli Lilly and Company920 enrolled303 locationsNCT07174336
Recruiting
Phase 3
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Breast Cancer
Stemline Therapeutics, Inc.4,220 enrolled524 locationsNCT06492616
Recruiting
Phase 2Phase 3
A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
Pancreatic Ductal Adenocarcinoma
Bristol-Myers Squibb470 enrolled277 locationsNCT07076121
Recruiting
Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY
Dravet SyndromeTuberous Sclerosis ComplexLennox Gastaut Syndrome
Jazz Pharmaceuticals100 enrolled18 locationsNCT05485831
Recruiting
Phase 1Phase 2
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
Breast NeoplasmsBreast DiseasesNeoplasms+5 more
Stemline Therapeutics, Inc.73 enrolled86 locationsNCT05386108
Recruiting
Upfront Targeted Axillary Dissection for Luminal Breast Cancer With Limited Axillary Involvement
Sentinel Lymph Node Biopsy (SLNB)ALNDTargeted Axillary Dissection (TAD)
European Institute of Oncology150 enrolled14 locationsNCT07278726
Recruiting
Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma
Nodal Marginal Zone Lymphoma
International Extranodal Lymphoma Study Group (IELSG)300 enrolled36 locationsNCT05700149
Recruiting
Emotional Distress in Patients With Metastatic Breast Cancer in First Line of Therapy
Metastatic Breast Cancer
European Institute of Oncology1,000 enrolled37 locationsNCT06994377
Recruiting
Phase 3
A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD)
Crohn's Disease (CD)
Takeda120 enrolled96 locationsNCT04779320
Recruiting
Phase 3
A Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD)
Crohn's DiseaseUlcerative Colitis
Takeda240 enrolled68 locationsNCT05442567
Recruiting
A Machine Learning Approach to Connect Multiple Myeloma Complexity to Early Disease Recurrence
Multiple Myeloma (MM)
IRCCS Azienda Ospedaliero-Universitaria di Bologna200 enrolled4 locationsNCT06767254